Incyte reported second-quarter 2026 GAAP total revenue of $1.67 billion and GAAP net income of $585.6 million, driven by higher product sales and a one-time accounting benefit related to Opzelura. Total net sales for the quarter were $1.49 billion, up 40% year-over-year, and the company raised full-year 2026 total net sales guidance to $5.13–$5.26 billion. Management also updated operating expense guidance to reflect the Vega Therapeutics acquisition and associated IPR&D expense expected in Q3 2026.

Financial Highlights

  • Total GAAP revenue: $1,674,039 thousand for the three months ended June 30, 2026 (38% increase vs. Q2 2025).
  • Total net sales: $1,488,149 thousand for Q2 2026 (40% increase vs. Q2 2025); total net sales and royalty revenues: $1,662,839 thousand (37% increase).
  • GAAP net income: $585,605 thousand for Q2 2026; GAAP diluted EPS: $2.81 for the quarter.
  • Non-GAAP net income: $643,359 thousand for Q2 2026; Non-GAAP diluted EPS: $3.09 for the quarter.
  • GAAP operating income: $697,898 thousand for Q2 2026; total GAAP operating income for six months: $999,015 thousand.

Business Highlights

  • Product momentum: Jakafi/Jakafi XR net sales were $816.7 million in Q2 (up 7% year-over-year); Opzelura net sales were $449.7 million (up 173% year-over-year), with a $246 million one-time non-cash reversal tied to a CMS settlement improving Opzelura's GTN profile.
  • Growth in hematology and oncology: Hematology and oncology portfolio net sales totaled $222 million in Q2, up 69% year-over-year, driven by Niktimvo, Monjuvi/Minjuvi and Zynyz demand.
  • Pipeline and clinical readouts: Ten clinical data readouts expected in H2 2026, including four registrational trials; multiple Phase 3 and Phase 1 updates across hematology, oncology and inflammation programs are planned.
  • Strategic acquisitions and partnerships: Completed acquisition of Vega Therapeutics, adding latarcibart for von Willebrand disease (Phase 3); entered collaboration with Halozyme for subcutaneous formulation work and expanded AI collaborations to accelerate discovery.
  • Regulatory and commercial milestones: Jakafi XR approved by FDA in May 2026; CHMP issued positive opinion for Opzelura in moderate atopic dermatitis in Europe; Minjuvi approved in Japan for relapsed/refractory DLBCL in June 2026.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.